Human Genome: FDA Reviews Lupus Drug
WASHINGTON, D.C. ( TheStreet) -- U.S. regulators posed some tough questions about the efficacy and safety of Human Genome Sciences' (HGSI) experimental lupus drug Benlysta in a review posted ahead of next Tuesday's advisory panel meeting.
Investors largely expect Human Genome Sciences and partner GlaxoSmithKline (GSK) to receive approval for Benlysta, which would be the first new treatment for the autoimmune disease lupus in about 50 years. To achieve the goal, however, Benlysta must first pass muster from a panel of outside experts and then receive final approval from the U.S. Food and Drug Administration.
Friday's medical review of Benlysta, posted on the FDA's web site, is the first step in this process. The FDA tends to take a prosecutorial role in its drug reviews ahead of advisory panel meeting, so investors largely anticipated the questions and concerns raised about Benlysta.
Across two large clinical trials, FDA acknowledged that two large clinical trials demonstrated a statistically significant difference in the number of lupus patients who responded to treatment with Benlysta compared to placebo. However, FDA said the results from the Benlysta studies produced "somewhat marginal efficacy" in part because the drug's biggest positive effect was on organ systems in patients that are not life threatening. The FDA also found that the study conducted outside the U.S. also produced stronger results than the study conducted here and African-Americans lupus patients underperformed relative to non-African Americans.The FDA also raised some concerns about Benlysta's safety, including risk for infections and neuropsychiatric adverse events including suicide. The specter of an increased risk of suicide was probably the most surprising revelation in the FDA material. "Clearly there is a need for effective therapies in SLE
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV